Aging in Custody

John R. Chamberlain, M.D.
Assistant Director, Program in Psychiatry and the Law
Associate Clinical Professor of Psychiatry
University of California San Francisco
Department of Psychiatry

Learning Objectives

At the conclusion of this presentation, the attendees will be able to:

- 1. Describe how the demographics of the incarcerated population (with regard to age) are changing.
- Discuss how the aging of the incarcerated population will affect the provision of healthcare in correctional settings.
- 3. Identify conditions that will be expected to become more common as the incarcerated population ages.
- 4. Discuss methods to better identify problems affecting the physical and mental health of older incarcerated individuals.

In the 1976 decision *Estelle v. Gamble*, the United States Supreme Court concluded that deliberate indifference to serious mental illness in a prisoner was a violation of the Eighth Amendment prohibition on cruel and unusual punishment.

The Court also concluded that denying medical care could lead to pain and suffering that no one proposed would serve a penological function.

Demographics


In 2010 11% of inmates in the United States prison population were 50 years and older


The incarcerated population in the United States is aging much more rapidly than the overall population in the United States.

From 1990 to 2009 the older adult population in the United States increased by over one half.

In 1990, 2 states had more than 1000 prisoners classified as older.

In 2009 that number had increased to 28







In 1990, there were 33,499 inmates 50 years and older in the United States prison system.

In 2001, there were 113,358 inmates 50 years and older in the United States prison system.

In 2010, there were 246,600 inmates 50 years and older in the United States prison system.

This represents an eight fold increase in two decades.

In 2010, 11% of inmates in the United States prison population were 50 years and older.

In a study published in 2001, Fazel, et al noted that the number of prisoners aged 60 and above in England and Wales had more than tripled in the prior decade.

They noted that, due to demographic changes and changes in sentencing practices, the population of elderly prisoners was expected to further increase.

They noted that, at the time of their study, elderly prisoners accounted for less than 2% of the total prison population.

In a 2011 study, Kingston, et al noted that between 2000 and 2009, the number of incarcerated men	
increased by 25.8% in England and Wales.	
During the same time period, the number of incarcerated men aged 60 and above increased by 109%.	
During that timeframe, the number of incarcerated women rose by 14.9%.	
However, the number of incarcerated women who were at least 50 years old increased by 173%.	
TEL	
Costs of an Aging Population	
costs of all Aging Population	
Compared with younger prisoners, it is estimated that it costs about three times more to incarcerate older prisoners.	
Much of this increased cost is the result of the cost of	
healthcare for older prisoners.	
Older prisoners commonly receive treatment for acute events associated with chronic disease in community hospitals.	
In 2009, California anont more than \$470 million for	
In 2008, California spent more than \$470 million for contract-based medical care outside of correctional facilities.	
Aging and Health	
Medications may impact functional status as people age.	
Anticholinergic medications and benzodiazepines have	
consistently been associated with problems in functional status among elderly individuals.	
Studies of the relationship between antidepressant	
medication use and declining functional status in the elderly were mixed.	
Studies of the relationship between functional status in elderly individuals and the use of antihypertensives	

The section is a first term of the section of the s	
The majority of physiological functions in youth have significant amounts of spare capacity.	
organican amount of sparo superior.	
We will refer to this energy conscitutes abusing and receive	
We will refer to this spare capacity as physiological reserve.	
A progressive decrease in this reserve is typical of even	
healthy aging.	
	-
Examples of such a decline include:	
Decreased explosive power of the lower limbs	
Decreased hepatic function	
Decreased glomerular filtration rate	
Decreased bone mass	
The decrease in physiologic reserve lessens a person's	
ability to react to situational and environmental	
challenges.	
Musele less (consensus) starts in middle and	
Muscle loss (sarcopenia) starts in middle age.	
Muscle loss progresses at about 1% annually.	
This is the result of muscle fiber loss which in turn	
may be due to progressive, partially compensated	
denervation.	
Even without gross renal disease, diabetes, or	
hypertension, increasing age is associated with loss of	
renal tissue.	
From birth until the fourth decade of life, renal mass	
increases in a progressive manner.	
	-
Renal mass subsequently decreases at a rate of 10%	
per decade.	
Renal mass is 20 to 30% (or more) less in the seventh	
and eighth decades of life than in the fourth.	

There is a reduction in functional glomeruli with aging.	
The effective surface area for filtration in the remaining glomeruli also decreases with age.	
After approximately age 40, renal blood flow	
decreases.	
The changes in glomerular filtration rate may not be	·
immediately apparent due to physiological reserve and the fact that creatinine production also declines.	9
The normal range of serum creatinine levels for healthy, young individuals is too high for elderly individuals.	
A serum creatinine of 1 mg/dL in a 20-year-old may	
represent an estimated glomerular filtration rate of 120 milliliters per minute but in an 80-year-old individual it may represent a glomerular filtration rate of 60 mL per min.	
Increasing age is typically associated with decreases in drug	
elimination by the kidneys.	
This decreased elimination is proportionate to decreases in creatinine clearance.	
Liver volume significantly decreases as people age.	
Liver blood flow decreases with age.	
There is a decrease in the number of hepatocytes with increasing age.	
There is a decrease in liver clearance of many drugs	
with increasing age.	
This decrease appears to be more related to decreased	
blood flow and liver size than to changes in enzyme activity.	

	1
There is evidence that increasing age is associated	
with hypoxia of hepatocytes.	
There is also evidence that oxidative stress results in decreased uptake of oxygen and decreased	
propranolol clearance compared to morphine	
clearance.	
Propranolol clearance involves oxidative metabolism	
while morphine clearance involves conjugation	
metabolism.	
These results support the idea that aging is associated	
with a restricted supply of oxygen which limits drug	
metabolism in the liver, especially oxidative metabolism.	
metabolism.	
Annual Communication of the Co	
There is a common perception that prisoners demonstrate	
accelerated aging when compared to community counterparts of	
the same chronological age.	
The health condition of incarcerated individuals has been	
suggested to approximate that of people 10 to 15 years older who are not incarcerated.	
Research has demonstrated that older prisoners (50 years and older) are more likely to have disability when compared with	
peers in the community.	-
Research has also demonstrated that older prisoners are more likely then peers in the community to have at least one chronic	
health problem.	
	_
A 2008 study indicated that:	
10% of older inmates have HIV/AIDS	
16% had tuberculosis	
32% had hypertension	
33% had arthritis	
A 2006 study indicated that:	
Mental health problems had been diagnosed in	
between 16 and 36% of older inmates.	

Hall transplaced		1	
Older prisoners have an average of thr	ee chronic medical		
problems.			
Compared with older non-prisoners and older prisoners have a greater burden	d younger prisoners, of disorders such as		
pulmonary disease, diabetes, and hype	ertension.		
46.7% of prisoners with at least three Texas are 55 and older.	chronic disorders in		
rexas are 55 and older.		-	
Prisoners in Texas who are age 55 and	older on average		
are chronically prescribed 7.3 classes of	of medications.		
17.11			
L- 2007 45 70/ -6 d4b- to -4-4-	(1.550)		
In 2007, 45.7% of deaths in state procedured among prisoners who were			
occurred among prisoners who were	e age 33 and older.		
70			
From 2001 to 2007:			
The death rate for prisoners age 45	to 54 years was		
559/100,000.			
The death rate for prisoners age 55	and older was		
2,123/100,000.			
	/ <u></u>		
The special section of the section o			
In a study published in 2001, Fazel,	et al studied male		
prisoners who were at least 60 year			
Approximately 85% of the prisoners	s consented to take		
part in the study.			
Health rated as good or very good o	on self-report:		
		<u></u>	
Prisoners 60 years old and older	36%	-	
Prisoners 18 to 49 years of age	61%		
Elderly men in the community	62%		
The second secon			

Taking prescribed			
Prisoners 60 year	rs old and older	77%	$\Delta = 0$
Prisoners 18 to 4	9 years of age	30%	
Elderly men in the	e community	68%	
Longstanding disa	ability or illness:		
Prisoners 60 year	rs old and older	83%	
Prisoners 18 to 4	9 years of age	46%	
Elderly men in the	e community	65%	
85% of the older p	orisoners had a mai	or illness listed	in their
85% of the older p medical records.			
Respiratory, muscu	uloskeletal, cardiova	ascular, and psy	ychiatric
illnesses were the the medical record	most common majors of the older prisor	ners.	tea in
Diagnosis		% of older pr	
Ischemic heart dise Hypertension	ease or angina	19.7% 13.3%	
Osteoarthritis		13.3%	
Diabetes mellitus		8.4%	
Chronic obstructive	e pulmonary diseas	e 6.9%	
Asthma		5.4%	
in,			
n a 2004 study, Fa	azel, et al reporte	d on medicati	on
n a 2004 study, Fa prescription in elde		d on medicati	on
prescription in elde	erly prisoners.		
orescription in elde System	Rx'd	Accurately Tar	
orescription in elde System Cardiovascular	erly prisoners. Rx'd , 35%	Accurately Tar 85%	
orescription in elde System Cardiovascular Musculoskeletal	erly prisoners. Rx'd , 35% 28%	Accurately Tai 85% 65%	
orescription in elde System Cardiovascular Musculoskeletal Gastrointestinal	erly prisoners. Rx'd 35% 28% 21%	Accurately Tai 85% 65% 58%	
orescription in elde System Cardiovascular Musculoskeletal Gastrointestinal Respiratory	erly prisoners. Rx'd 35% 28% 21% 13%	Accurately Tar 85% 65% 58% 61%	
orescription in elde System Cardiovascular Musculoskeletal Gastrointestinal	erly prisoners. Rx'd 35% 28% 21%	Accurately Tai 85% 65% 58%	
orescription in elde System Cardiovascular Musculoskeletal Gastrointestinal Respiratory Psychiatric	erly prisoners. Rx'd 35% 28% 21% 13% 9%	Accurately Tai 85% 65% 58% 61% 18%	
orescription in elde System Cardiovascular Musculoskeletal Gastrointestinal Respiratory	Rx'd 35% 28% 21% 13% 9% prisoners with a	Accurately Tar 85% 65% 58% 61% 18% recorded	rgeted

In a 2006 study, Williams, et al noted that there had been a 350% increase in the population of incarcerated geriatric women	
in the prior decade	
Age 55 was used to define geriatric.	
They noted that a third of the entire prison population in the United States was projected to be geriatric by 2030.	•
Female geriatric prisoners have greater rates of comorbid disorders than males.	
Older age and female gender most strongly predict elevated use of medical services and morbidity.	
33% of the female prisoners reported having at least three comorbid conditions.	
78% of the female prisoners took at least five	
medications.	
22% of the female prisoners reported having incontinence.	
28% of the female prisoners reported having experienced memory loss.	
52% of the female prisoners reported having impaired	
hearing.	
58% of the female prisoners reported having impaired vision.	
16% of the female prisoners required assistance with at least one ADL.	
This rate is twice that of the general population (age 65 and above) in the United States.	
69% of the female prisoners indicated that one or more PADL was quite difficult to perform.	
Many of these latter women did not report needing assistance with ADLs.	
assistance with ADLs.	

	=
Mental Health of Older Prisoners	
In a 2011 study, Kingston, et al noted that 1.6% of older prisoners were diagnosed with dementia by the GMS.	
This was slightly above the rate expected for same aged peers living in the community.	
They noted there is evidence that long-term incarceration results in cognitive impairment.	
They also note that some prisoners who are sent to a hospital with a presumed dementia diagnosis demonstrate an elevation in their scores on the MMSE in the initial few months after transfer.	
One study revealed that prisoners with cognitive impairments were identified by correctional officers at a nearly five fold greater rate than by prison officials.	
Risk factors for cognitive impairment include a history	
of traumatic brain injury, posttraumatic stress disorder, and substance abuse.	-
These conditions are common among prisoners.	
Side effects from medication as well as poor diets	
resulting in deficiencies of vitamins may also increase the risk for dementia among prisoners.	
Prisoners are at a significantly higher risk for dementia	
due to poor mental health and poor physical health status.	
Public spending on the care for individuals with	
dementia is estimated to have reached up to \$202 billion.	
13% of people age 65 and above in the United States	
are estimated to have some level of dementia.	
Estimates of the prevalence of dementia in the prison population in the United States range from 1 to 44%.	
It has been estimated that the number of incarcerated individuals with dementia will double by 2030 and will triple by 2050.	

	One study revealed a 40% rate of cognitive	
	impairment was noted in the medical records of prisoners age 55 years and older.	
	prisoners ago de yours and older.	-
	This prevalence was substantially greater than that of adults of the same age living in the community.	
	dualis of the same age irring in the community.	
	Health care services specific to the geriatric population were only provided in 4% of state institutions according to a 2002 paper by Maschi, et al.	
	according to a 2002 paper by mascrif, et al.	
,		
1		1
	FOX of incorporated individuals FO to FA years of	
	50% of incarcerated individuals 50 to 54 years of age have problems related to mental health.	
	2/0/-5 in a second in the third con EE and above	
	36% of incarcerated individuals age 55 and above have problems related to mental health.	
	One third of the individuals in each group will have treatment available to them while in prison.	
	treatment available to them while in prison.	
	In another study by Fazel, et al, it was noted that a prior	
	retrospective study had found that 55% of prisoners over age 65 had symptoms of a mental health condition.	
	They also noted that epidemiological surveys had revealed that 10% of elders in the community had a mental illness	
	while 5 to 10% had dementia.	
	Fazel, et al's study was based on the same population of male prisoners at least 60 years of age as the study	
	reviewed previously.	
	The Geriatric Mental State or GMS and the Structured Clinical Interview for DSM-IV Axis II personality disorders	
	were used to assess the prisoners.	

Reception health screening data and medical re reviewed.	cords were
Tevieweu.	
31.5% of the prisoners were found to have psy	chiatric
illness based on the GMS.	
29.6% of the prisoners were found to have a de disorder making it the most common diagnosis.	
alsorder making it the most common diagnosis.	ADTS:
40% of the prisoners with a depressive disorde	r based on
the GMS had a present or past history of depre-	ssion listed
in the medical record.	
76.8% of the prisoners were using some type of	of prescribed
medication.	, prescribed
11.7% of the prisoners diagnosed with depress GMS were receiving antidepressant medication.	ion on the
- Givis were receiving antidepressant medication.	7.75
30% of the prisoners received a diagnosis of a	personality
disorder based on the SCID-II.	
9.4% of the prisoners had comorbid psychiatric personality disorder.	illness and
53.2% of the prisoners received a psychiatric d	iagnosis.
	f Prisoners
Antisocial personality disorder	8.3%
Obsessive-compulsive personality disorder	7.9%
Avoidant personality disorder	8.3%
Schizoid personality disorder	6.4%
Mixed personality disorder	6.9%
	partition (
In another study, 64% of prisoners aged 18	to 65 had
been found to have a personality disorder on	
	specifical residence

S	n a 2011 study, Kingston, et al noted that in a prior tudy a little over half of incarcerated men at least 55 ears of age received scores greater than the	
	iagnostic threshold for a mild depression.	
K	ingston, et al studied prisoners aged 50 and above.	
N S	he Geriatric Mental State Examination or GMSE, the lini-Mental State Examination or MMSE, and the hort-Form 12 or SF-12 were utilized to assess the risoners.	
N St	ledical records and data from reception health creening were also reviewed.	
		1
	sing the GMS, 49.6% of the prisoners were found to ave a diagnosable psychiatric illness.	
	epressive disorder was the most common psychiatric iagnosis, accounting for 83% of the diagnoses.	
4	2.1% of the prisoners self-reported having a problem	
	elated to mental health.	
	0% of the prisoners had psychotropic medication	
16	ecorded in their medicarrecord.	
	f note, all of the prisoners receiving psychotropic edication were diagnosed with depression.	
0.00	5% of them were receiving antidepressant dedication.	
P	risoners who self-reported a prior mental illness	
	istory and those with violent offenses had higher sks of having depression.	
	risoners older than 65 years of age had a higher rate f depression than those under 65 years of age.	
Р	hysical health was not associated with depression.	

In a 2008 study, Murdoch, et al evaluated incarcerated	
men at least 55 years of age who were serving either indeterminate or life sentences.	
The Geriatric Depression Scale was utilized to assess depressive symptoms.	
The Mini Mental State Examination was used to assess cognitive function.	
48% of prisoners had scores in the mild range of depression.	
3% of prisoners had scores in the severe range of depression.	
	1
Of note, 56% of prisoners who scored below the mild range of depression had a score of 10 points on the GDS.	
95.	
This score is the cut-off or borderline between mild and no depression.	
The scores on the GDS were not related to the length of the prison term served.	
In a survey of individuals above age 65 in general practice, 35% had depression.	
Higher GDS scores were associated with: Being prescribed >4 medicines (except antidepressants)	
Chronic illness (illnesses in the prior 12 months,	
hypertension, ischemic heart disease, and hypercholesterolemia)	
Prisoner ratings of healthcare as being unsatisfactory	
Previous history of mental illness (this included substance abuse, anxiety, and depression)	
A previous history of depression did not have a greater effect than the presence of other previous psychiatric	
diagnoses	
Lower MMSE score	

		•	
Williams of all found that increasi	ng functional		
Williams, et al found that increasii impairment was associated with fe	eelings of depression		
in older female prisoners.	3		
	- A		
Level of Impairment % R	Reporting Depression		
No functional impairment	19%		
A PADL impairment	40%		
ADL impairment	53%		
Safety and Sec	curity		
Prisoners with dementia may have	e deficits in areas		
such as executive function, visual	processes,		
language, and reasoning which mater to e	ay impair their ability		
or prison authorities.	ither prisoner leaders		
Auditory difficulties may also impa	air the ability of older		
prisoners to respond appropriately	<i>y</i> .		
Individuals with dementia are more	re vulnerable to		
victimization by their peers in pris	on.		
Individuals with dementia may ex	hibit agamasian		
	nibit aggression		
toward other prisoners or staff			
toward other prisoners or staff.			
toward other prisoners or staff.	"dE		
toward other prisoners or staff.			
toward other prisoners or staff.			
toward other prisoners or staff.		-	
toward other prisoners or staff.		-	
toward other prisoners or staff.	Drisonors		
Identifying at Risk	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		
toward other prisoners or staff.	Prisoners		

1. Is there evidence of an acute change in mental status from the patient's baseline? 2A. Did the patient have difficulty focusing attention, for example, being easily distractible, or having difficulty keeping track of what was being said? **2B.** Did this behavior fluctuate during the interview, that is, tend to come and go or increase and decrease in severity? 3. Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject? 4. Overall, how would you rate this patient's level of consciousness? (Alert [normal]: Vigilant [hyperalert, overly sensitive to environmental stimuli, startled very easily], Lethargic [drowsy, easily aroused]; Stupor [difficult to arouse]; Coma; [unarousable]; Uncertain) **6.** Did the patient demonstrate any memory problems during the interview, such as inability to remember events in the hospital or difficulty remembering instructions? 7. Did the patient have any evidence of perceptual disturbances, for example, hallucinations, illusions or misinterpretations (such as thinking something was moving when it was not)? 8A. At any time during the interview did the patient have an unusually increased level of motor activity such as restlessness, picking at bedclothes, tapping fingers or making frequent sudden changes of 9. Did the patient have evidence of disturbance of the sleep-wake cycle, such as excessive daytime sleepiness with insomnia at night?

ISUOSPATIAL / EXECUT	IVE	5590		Draw	CLOCK (Ten	past nine)	POINTS.
@	0	~	py cylinder	f. 8 protein	40.5		
_ @	C	()	()	1			
2 (A)	3 4			1			
① ③	0			1			
(E)	0			1			
tind	1 1		1.1	Contour	I I	era Hamda	75
EM	M. 6	It M.	5	A	Tr		_/3
egisial Userii. Dio 2 (vials, even f lo a recali after 5 ennutes.	The state of the s	1 st trial 2nd trial	ANN EGG			HAIR BLUE	Page points
repeat them. Do 2 trials, even if hi a recall after 5 consides. ATTENTION Read I	Tell Modile nurroreally.	2nd trial 2nd trial 3. Subject has to a Subject has to a	rymat Charry in the	Not pussed until	ler [1 1 5 4 1 8 7 1 1 7 4	Page points
repeat them. Do 2 trials, even if hi a recall after 5 consides. ATTENTION Read I	"Self blodies numberedist. Text of dilights (1 dilight/ see, thank for boys with him frank)	1 st trial 2 sol trial 3. Subject has to a Subject has to a I at each lesser A. No po	rymat Charry in the	herman) and backward o	nter [154187	points.
egecat them. Do 2 titals, even f to a recall after 5 executes.	1 of trial is noncessful. Tel: of slights (1 slight/ sec. There's Sep with the twent	1 st trial 2 rod trial 3. Subject has to: Subject has to: (at each tester A. Hope () F B	qual there is the qual there is the act of \$20000 ACMNAAJE	LBAFA	OEAAAI	154187	_/2 /1
regional theory. Do 2 years, even if no a result offer 5 econocies. ATTENTION Result is considered. The subjects of testing of test	Tel Holdin successful. Tel of eligita (1 eligit/ ten. eneral Sep with the tweet (80 []]	1 st trial 2nd trial 3. Subject has to a Subject has to a set can't letter A. No pe [] F 8 73 [] J 66 4 or b common value	post there is the post of the post there is the post there is the post of the	LBAFA)	OEAAAI	1 5 4 1 8 7 1 1 7 4 AMOFAAN	_/2 /1
report them. Do 2 trust, most of its a security offer 5 enterates. ATTENTION floraid its control for a security of the securi	Tel Mildia surpresentation of elliptic (1 steph) have charact hope with the function and (1 Stee Neward Int.) Surpresent The Mildia girth with a more newards of words in more resembles of words in	2nd trial 2nd trial 3. Subject has to a subject has	reposed theory in the good fluority in the control of C	LBAFA)	in [coenani	1 5 4 1 8 7 1 1 7 4 AMOFAAN [] 45	/2 /1 /3 /1
system Described Dr. 2 (vol. month) ATTENTION Break Dr. ATTENTION Break Dr. AND	Tot Notice successful. Into of digits (1 digits) has of original to digits (1 digits) has of original to the	1st trial 2red trial 3. Subject has to r Subject has to re [] F 8 73	rymet them in the great them in the control of the	LBAFA)	COEAAA	1 5 4 1 8 7 1 1 7 4 (AMOFAAII 1 45 4 pt (cores) 0 pt	/2 /1 4/3 /2
report them. Do 2 trust, most of its a security offer 5 enterates. ATTENTION floraid its control for a security of the securi	Tot Notice successful. Into of digita (1 degits) for the second	2nd trial 2nd trial 3. Subject has to a subject has	reposed theory in the good fluority in the control of C	LBAFA)	COEAAA	1 5 4 1 8 7 1 1 7 4 AMOFAAN [] 45	/2 /1 /3 /1
pages them Do 2 roots must be a second property of the second proper	Tot Notice successful. Into of digita (1 degits) for the second	Text trial 2. Subject has to a Subject	rymet them in the great them in the control of the	CLBAFA)	COEAAA	AMOFAAB [] 45 AMOFAAB] 45 	/2 /1 4/3 /2

GERIATRIC DEPRESSION SCALE:

Choose the best answer for how you have felt over the past week:

- 1. Are you basically satisfied with your life? YES / NO
- 2. Have you dropped many of your activities and interests? **YES** / NO
- 3. Do you feel that your life is empty? YES / NO
- 4. Do you often get bored? YES / NO
- 5. Are you in good spirits most of the time? YES / NO

- 6. Are you afraid that something bad is going to happen to you? **YES** / NO
- 7. Do you feel happy most of the time? YES / NO
- 8. Do you often feel helpless? YES / NO
- 9. Do you prefer to stay at home, rather than going out and doing new things? **YES** / NO
- 10. Do you feel you have more problems with memory than most? $\ensuremath{\mathbf{YES}}$ / NO

11. Do you think it is wonderful to be alive now? YES / NO	
12. Do you feel pretty worthless the way you are now? YES / NO	
13. Do you feel full of energy? YES / NO	
14. Do you feel that your situation is hopeless? YES / NO	
15. Do you think that most people are better off than you are? YES / NO	-
Answers in bold indicate depression. A score of > 5 points suggests depression; do a follow-up interview. Scores of > 10 are nearly always due to depression.	
Treatment Interventions	
A study conducted in 2010 of inmates in the New Jersey Department of Corrections revealed that	·
greater mental well-being was reported by older inmates who reported having greater levels of both external and internal coping resources in social,	
spiritual, physical, emotional, and cognitive domains.	
The authors concluded that it was necessary to assess	
inmates for present and past stress and trauma as well as re-traumatization and neglect occurring in institutional and healthcare settings.	
The authors also concluded that assessment of past and present coping strategies was necessary to improve the mental well-being of inmates.	
improve the mental wen-being of initiates.	

In 2005, the FDA determined there was a significantly	
increased risk of mortality (when compared with	
placebo) among elderly individuals with dementia who were treated with atypical antipsychotics.	
The increased risk of mortality was a factor of 1.6 to	
1.7.	
Most of the deaths were the result of infectious or	
cardiac causes.	
Delusions occur in 9 to 63% of individuals with	
Alzheimer's disease.	
Hallucinations occur in 4 to 41% of individuals with	
Alzheimer's disease.	
Physical aggression occurs in 31 to 42% of individuals	
with dementia in institutions.	
Agitation occurs in 20 to more than 80% of individuals	
with dementia.	
Atypical antipsychotics have demonstrated modest	
efficacy in the treatment of psychosis associated with Alzheimer's disease.	
Augmenter 3 disease.	
However, no atypical antipsychotics are indicated for the treatment of psychosis associated with dementia.	
Moreover, studies have not uniformly demonstrated that atypical antipsychotics outperform placebo in	
treating psychotic symptoms in individuals with Alzheimer's disease.	
Alzheimer 5 disease.	
Hasan and half the section of section of	
Unfortunately both the safety and efficacy of alternative treatments (including behavioral/	
psychosocial and pharmacological interventions) for	
agitation and/or psychosis complicating dementia is still unclear.	
It is worth noting that there is generally a 30 to 40% response rate for placebo in randomized clinical trials	
of antipsychotics in dementia.	
It is felt to be likely that non-specific therapeutic	
factors account for a significant proportion of this	
improvement.	

It is important to realize that there are no known specific protective factors for deaths or for cerebrovascular adverse events associated with antipsychotics in this population. It is important to realize that there are no known specific risk factors for deaths or for cerebrovascular adverse events associated with antipsychotics in this population. The effects of memantine and cholinesterase inhibitors on behavior are not clear but appear to (at best) be modest. A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Abhelmer's disease that was moderate to severe, significant agitation was not improved by Memantine.
specific protective factors for deaths or for cerebrovascular adverse events associated with antipsychotics in this population. It is important to realize that there are no known specific risk factors for deaths or for cerebrovascular adverse events associated with antipsychotics in this population. The effects of memantine and cholinesterase inhibitors on behavior are not clear but appear to (at best) be modest. A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus altypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
cerebrovascular adverse events associated with antipsychotics in this population. It is important to realize that there are no known specific risk factors for deaths or for cerebrovascular adverse events associated with antipsychotics in this population. The effects of memantine and cholinesterase inhibitors on behavior are not clear but appear to (at best) be modest. A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
specific risk factors for deaths or for cerebrovascular adverse events associated with antipsychotics in this population. The effects of memantine and cholinesterase inhibitors on behavior are not clear but appear to (at best) be modest. A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
specific risk factors for deaths or for cerebrovascular adverse events associated with antipsychotics in this population. The effects of memantine and cholinesterase inhibitors on behavior are not clear but appear to (at best) be modest. A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
The effects of memantine and cholinesterase inhibitors on behavior are not clear but appear to (at best) be modest. A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
A Cochrane review from 2011 concluded there were few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
few studies regarding the use of antidepressants to treat psychosis and agitation in dementia at present. It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
It was noted that, in two studies, citalopram and sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
sertraline had been associated with decreased agitation versus placebo. It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
It was noted that Trazodone and SSRIs seem to be reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
reasonably well tolerated versus atypical antipsychotics, typical antipsychotics, and placebo. A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
A 2012 study found that, in individuals with Alzheimer's disease that was moderate to severe,
Alzheimer's disease that was moderate to severe,
Alzheimer's disease that was moderate to severe,
significant agitation was not improved by Memantine.
A 2014 study, examined individuals with probable Alzheimer's disease as well as clinically significant
levels of agitation.
All of them received a psychosocial intervention.
94 received Citalopram and 92 received placebo for nine weeks.
This was a double-blind, placebo-controlled,
randomized trial.
Citalopram dosing began at 10 mg and could be
Citalopram dosing began at 10 mg and could be increased to 30 mg daily over a period of three weeks.

A TO STATE	ATTEN		
Final Thoughts/Discuss	ion Points		
Treatment of depression			
Treatment of psychosis			
Treatment of anxiety			
Treatment of bipolar disorder			
Treatment of delirium			
Questions?			
Questions			
	_		
References			
halt, C, et al. Paying the Price: The Pressing N outcomes Data to Improve Correctional Health AGS. 2013; 61: 2013-9.	eed for Quality, Cost, and Care for Older Prisoners.		
Bolignano D, et al. The aging kidney revisited:	A systematic review.		
usack BJ. Pharmacokinetics in Older Persons harmacother. 2004; 2: 274-302.			
harmacother. 2004; 2: 274-302. stelle v. Gamble., 429 U.S. 97 (1976).			
azel S, et al. Hidden psychiatric morbidity in e ournal of Psychiatry. 2001; 179: 535-9.	lderly prisoners. British		
azel S, et al. Health of elderly male prisoners: opulation, worse than younger prisoners. Age 03-7.	worse than the general and Ageing. 2001; 30:		
Fazel S, et al. Dementia in prison: ethical and lo Ethics. 2002; 28:156-9.	egal implications. J Med		
Fazel S, et al. Unmet treatment needs of older	prisoners: a primary care	-	

References

Fox C, et al. Efficacy of Memantine for Agitation in Alzheimer's Dementia A Randomised Double-Blind Placebo Controlled Trial. PLoS ONE. 2012; 7(5): e35185

Jeste DV, et al. ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia. Neuropsychopharmacology. 2008; 33:957-70.

Kingston P, et al. Psychiatric morbidity in older prisoners: unrecognized and undertreated. International Psychogeriatrics. 2011; 23(8): 1354-60.

Maschi T, et al. Forget Me Not: Dementia in Prison. The Gerontologist. 2012; 52(4): 441-51.

Maschi T, et al. Unraveling Trauma and Stress, Coping Resources, and Mental Well-Being Among Older Adults in Prison; Empirical Evidence Linking Theory and Practice. The Gerontologist.2013; doi: 10.1093/geront/gnt069.

Murdoch N, et al. Int J Geriatr psychiatry. 2008; 23:957-62

References

Peron EP, et al. Medication Use and Functional Status Decline in Older
Adults: A Narrative Review, Am J. Geriatr Pharmacother, 2011, 9: 378-91

Porsteinsson, AP, et al. Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial. JAMA. 2014; 311(7): 682

Seitz DP, et al. Antidepressants for agitation and psychosis in dementia (Review). The Cochran Collaboration. 2011; 2.

Waszynski CM. Confusion Assessment Method (CAM). Dermatology Nursing. 2004;16(3).

Williams BA, et al. Being Old and Doing Time: Functional Impairment and Adverse Experiences of Geriatric Female Prisoners. JAGS. 2006; 54:702-7-

Williams BA, et al. Addressing the Aging Crisis in U.S. Criminal Justice Health Care. JAGS. 2012; 60: 1150-6.

Young A. Ageing and physiological functions. Phil. Trans. R. Soc. Lond. B. 1997; 352: 1837-43.